Table 2 Haematological toxicities (worst grade per patient)

From: Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer

Adverse event

Dose level (mg m−2)

Grade 0

Grade 1

Grade 2

Grade 3

Grade 4

Neutrophils

5

1

0

0

0

0

 

10

1

0

0

0

0

 

20

1

0

0

0

0

 

35

4

1

1

1

0

 

50

1

2

1

1

1

 

70

1

0

2

0

4

 

90

0

0

0

0

3

Leucocytes (WBC)

5

1

0

0

0

0

 

10

1

0

0

0

0

 

20

0

1

0

0

0

 

35

4

1

1

1

0

 

50

2

1

1

1

1

 

70

1

1

1

2

2

 

90

0

0

0

1

2

Haemoglobin

5

1

0

0

0

0

 

10

1

0

0

0

0

 

20

0

1

0

0

0

 

35

1

3

2

1

0

 

50

1

2

3

0

0

 

70

2

1

4

0

0

 

90

0

1

1

1

0

Platelets

5

1

0

0

0

0

 

10

1

0

0

0

0

 

20

1

0

0

0

0

 

35

5

2

0

0

0

 

50

3

2

0

1

0

 

70

4

1

1

1

0

 

90

1

1

1

0

0